Drtech

At a glance

Drtech filed 43 disclosures in the last 12 months, including 6 5% holder, 3 insider, 3 issuance and 1 buyback. The most recent key filing was on Sep 10.

Revenue for 2025 was ₩116B, up 19.2% on 2024. It made an operating loss of ₩13.9B. Debt was 163% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩68.9B and operating profit of ₩1.3B.

The 2025 annual report lists 381 employees with an average tenure of 4 years and average pay of ₩52.2M, #1353 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩144M each on average. It paid no cash dividend for 2025. 윤정기 and related parties held 6.44% at year end.

From the 2025 annual report

Staff: 381 (305 men, 76 women), of whom 3 on fixed-term contracts. Total pay for the year: ₩19.9B. Directors and auditors: 7, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

윤정기 holds 6.44%; with 1 related party the group holds 6.44% of common shares at year end (from 6.98% at the start of the year).

Auditor: 서우회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary